Open label comparison of injectable buprenorphine (CAM2038 Brixadi ) and naltrexone (Vivitrol ) for opioid use disorder
Recruiting
99 years and younger
All
Phase
2
200 participants needed
1 Location
Brief description of study
Compare brain fMRI response to injectable extended-release buprenorphine (Brixadi, XR-BUP) and naltrexone (XR-NTX, Vivitrol) Our primary outcome combines adherence to treatment and the frequency of illicit opioid use during treatment. The primary outcome is a binary indicator of treatment success: Participants who provide 2 weekly UDS positive for opioids or reports of two or more periods of 3 days of opioid use in the 3rd (last) month of treatment, is late for more than 2 weeks for XRNTX or XRBUP treatment, or drops out of treatment prior to the 3rd injection, will be classified as treatment failures; otherwise, they will be classified as a treatment success. Test an integrated brain-behavior model of relapse vulnerability in OUD; ASI composite scores; effects of Group and neural change variables on other substance use outcomes
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: opioid use disorder
-
Age: - 99 Years
-
Gender: All
Updated on
01 Aug 2024.
Study ID: 843403
Find a site
,
You have contacted , on
Your message has been sent to the study team at ,
A copy of the message has been sent to your email
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting